Saeed aghebat bekheir

Dr. Saeed aghebat bekheir

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Human & Experimental Toxicology
Verified
Journal Article
Open access
SBSaeed aghebat bekheir
Saeed aghebat bekheir
MAMohammad Abdollahi
Mohammad Abdollahi
Introduction: Aluminum phosphide (AlP) is a chemical compound that can cause death in some countries. AlP inhibits the functioning of cytochrome C oxidase in the mitochondria of cardiomyocytes, leading to toxicity. Oxidative stress and ROS production, as well as inflammatory signaling, mediate the mechanisms of AlP-related toxicity in the poisoned patient. Unfortunately, there are no approved medicines available to treat AlP poisoning yet. To address this issue, researchers have explored various interventions to reduce the toxicity associated with AlP tablets. Methods: We systematically searched relevant databases for English articles published between 2013 and 2024. Results: The evaluated treatments included correcting oxidative stress parameters, enhancing exogenous antioxidant capacity, modifying electrocardiographic abnormalities, and improving heart contraction strength. Our evaluation indicated that compounds like Triiodothyronine, Vasopressin and milrinone, Iron sucrose, Acetyl-l-carnitine, Melatonin, Fresh red blood cell transfusion, Minocycline, Moringa oleifera extract, Dihydroxyacetone, Selegiline, Nanocurcumin, Levosimendan, Exenatide, Taurine, Cannabidiol and Edaravone are effective in lessening AlP-induced cardiotoxicity. Conclusion: Based on the present study’s findings and the evaluation of clinical studies, dihydroxyacetone, fresh red blood cell infusion, Oil-based disinfection, and gastric lavage have the most potential to save patients’ lives and treat acute aluminum phosphide. However, there is a need for more research in this regard.

27 February 2026 in Journal of Food Protection
Verified
Journal Article
Open access
BMBahare Mohamadi
Bahare Mohamadi
BABehrouz Akbari-Adergani
Behrouz Akbari-Adergani
NVNarges Velayati
Narges Velayati
ABAlireza Bakhtiyari
Alireza Bakhtiyari
SBSaeed aghebat bekheir
Saeed aghebat bekheir
PSParisa Sadighara
Parisa Sadighara
Chloramphenicol (CAP) is a broad-spectrum antibiotic with applications in human and veterinary medicine. However, due to its severe adverse effects, including fatal aplastic anemia, its use in food-producing animals has been banned in many countries. Despite these regulations, CAP residues have been detected in milk, raising concerns about food safety and regulatory compliance. This systematic review aimed to evaluate the presence of CAP in milk, detection methods, and regulatory limits. A comprehensive literature search identified 918 studies, of which 27 met the inclusion criteria. The included studies primarily focused on analytical methodologies for CAP detection in milk samples, with techniques such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), high-performance liquid chromatography (HPLC), and enzyme-linked immunosorbent assays (ELISA) being the most commonly employed. LC-MS/MS demonstrated the highest sensitivity and accuracy. While 55.5% of studies reported no CAP detection, others indicated varying levels, with some exceeding regulatory limits. The findings highlight the ongoing challenge of CAP contamination in milk and the necessity for stringent monitoring and regulatory enforcement. Further research is needed to improve detection capabilities and assess the public health risks associated with CAP residues in dairy products.

12 November 2025 in Molecular & Cellular Toxicology
Verified
Journal Article
Closed access
PDF file
SBSaeed aghebat bekheir
Saeed aghebat bekheir
SHShirin Hekmatirad
Shirin Hekmatirad
NANasim Assar
Nasim Assar
MAMohammad Abdollahi
Mohammad Abdollahi

23 January 2025 in Natural Product Communications
Verified
Journal Article
Open access
ZMZahra Meraati
Zahra Meraati
MAMahsa Ale-Ebrahim
Mahsa Ale-Ebrahim
PMPejman Mortazavi
Pejman Mortazavi
ACAli Chitgar
Ali Chitgar
SBSaeed aghebat bekheir
Saeed aghebat bekheir
Objective/background: The main side effect of gentamicin, an aminoglycoside antibiotic, is kidney toxicity. This side effect leads to electrolyte disorders and retention of nitrogen waste products such as urea and creatinine. This study aimed to investigate the protective effect of the hydroalcoholic extract of the walnut tree ( Juglans regia) on gentamicin-induced nephrotoxicity in male Wistar rats. Methods: The experiment involved five groups of rats: a control group, a gentamicin-treated group, and three groups treated with different doses of walnut leaf extract (100, 200, or 400 mg/kg) via intragastric gavage for 14 consecutive days (once per day). After 14 days, blood samples were collected and analyzed for various biochemical markers. Kidney tissue was also examined histopathologically. Results: Findings showed that gentamicin significantly increased levels of uric acid ( P < .001), urea ( P < .001), creatinine ( P < .01), albumin ( P < .001), and lipid profile while decreasing the activity of antioxidant enzymes SOD ( P < .001) and CAT ( P < .001) compared to the control group. It also caused kidney tissue damage. Treatment with walnut leaf extract could significantly reduce urea in all treatment groups. However, the reduction in creatinine levels after treatment with walnut leaf extract wasn’t significant. Further, walnut leaf extract at doses of 200 and 400 mg/kg could significantly reduce albumin and uric acid levels ( P < .001). Walnut leaf extract significantly improved lipid profile. Also, walnut leaf extract significantly increased SOD and CAT activity in all doses. Walnut leaf extract significantly reduced kidney tissue damage, including inflammation, necrosis, and tubular degeneration. Conclusion: The results of this study conclude that walnut tree leaf extract positively affects kidney function and histology in gentamicin-treated rats. This extract or similar compounds could be an antioxidant treatment for people with renal impairment or chronic kidney disease.

21 August 2026 in Measurement: Food
Verified
Journal Article
Open access
BMBahare Mohamadi
Bahare Mohamadi
NANader Akbari
Nader Akbari
PMParia Miri
Paria Miri
SSSamira Shokri
Samira Shokri
SBSaeed aghebat bekheir
Saeed aghebat bekheir
PSParisa Sadighara
Parisa Sadighara

30 March 2026 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
HBHelia Behrouzfar
Helia Behrouzfar
PMPejman Mortazavi
Pejman Mortazavi
SHShokoufeh Hassani
Shokoufeh Hassani
SBSaeed aghebat bekheir
Saeed aghebat bekheir
Introduction: Alzheimer’s disease (AD) is a widely prevalent and neurodegenerative disorder that leads to dementia and mortality worldwide. Previous investigations have reported the beneficial effects of physical exercise on brain function, linked to anti-inflammatory effects in the brain vasculature and elevated BDNF production. Empagliflozin, a conventional antidiabetic agent, has shown potential neuroprotective properties in the central nervous system, evidenced by its ability to elevate BDNF and mitigate oxidative stress and inflammation. Materials and Methods: In the present investigation, AD was induced in control, exercise, empagliflozin (10 mg/kg BW, PO), and combined intervention groups using intrahippocampal injections of an amyloid-beta (Aβ) prepared solution via stereotaxic surgery. The therapeutic effects of each treatment, exercise alone, empagliflozin alone, and exercise plus empagliflozin, were studied. After 28 days, spatial memory tests were used to assess memory and learning. Furthermore, histopathological (H&E and Congo red) and immunohistochemical (GFAP) analyses were performed, and the ADP/ATP ratio in isolated brain mitochondria was measured by HPLC. Results: Our results showed that the combined program of physical training and empagliflozin treatment in the Aβ-induced AD model drastically improved cognitive functions and neurological parameters, including target-finding time, traveled distance, time spent in the target quadrant, and ADP/ATP ratios in brain mitochondria. Additionally, it diminished necrotic cell death and reduced Aβ plaques but did not notably affect astrocyte activity. Discussion: Exercise and empagliflozin, by affecting mitochondrial energy balance and reducing amyloid deposition, play key roles in mitigating AD pathophysiology. Conclusion: The combined effects of the treatments used in this experimental method yielded significant improvements in cognitive functions. These findings provide a basis for further clinical studies for the exploration of the synergistic impact of the aforementioned therapeutic methods.